ACCESS Newswire

Empower Clinics Inc.

21.7.2021 10:37:39 CEST | ACCESS Newswire | Press release

Share
Empower Announces Sale of Its Cannabis Related Assets

Exclusive non-binding term sheet signed to allow Empower to fully divest of its cannabis businesses

VANCOUVER, BC / ACCESSWIRE / July 21, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens - The company has received and signed a non-binding term sheet to enter into an agreement that would allow Empower to divest of its legacy cannabis assets and fully focus on its integrated healthcare business.

The associated non-binding agreement outlines that Andrea Klein and Dustin Klein (together the "Kleins") will acquire 100% of Sun Valley Health Holdings LLC, Sun Valley Health Franchising, LLC, Sun Valley Health, LLC, Sun Valley Health West, LLC, Sun Valley Health Tucson, LLC, Sun Valley Health Mesa, LLC, Sun Valley Alternative Health Centers NV, LLC, and all subsidiaries thereof (together "Sun Valley").

"This transaction will allow Empower to complete the divestment of its legacy cannabis assets and focus on its integrated healthcare vision", said Steven McAuley. "We also expect this divestment to allow Empower to engage with a different breadth of partners - such as banks, auditors and advertising companies - who had restrictions against engaging companies in the cannabis space".

The structure of the agreement is on a cash-free, debt-free basis wherein the consideration of $1,000,000 USD, is to be settled by the transfer from the Kleins to, or as directed by, the Seller, of such number of common shares in the capital of Empower (each, a "Share") as is equal to $1,000,000 USD divided by the United States dollar equivalent (based on the Bank of Canada daily exchange rate for the conversion of Canadian dollars to United States dollars on the applicable date) of the volume weighted average trading price of the Shares on the Canadian Securities Exchange (the "CSE") for the 10 trading days ending on the date that is two business days prior to the date of closing of the Acquisition (collectively, the "Consideration Shares").

Completion of the transaction is subject to customary closing conditions, including completion of due diligence, negotiation of definitive agreements and receipt of all necessary approvals. If such conditions are not satisfied it is possible that the proposed transaction will not be completed on the terms set forth herein or at all. The parties anticipate completing the definitive agreements within the next 30 to 60 days.

This non-binding transaction will permit Empower to robustly pursue its integrated health plan through initiatives such as the national clinic expansion and Kai Care Testing Solutions, along with an aggressive acquisition strategy.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:

Steven McAuley CEO
s.mcauley@empowerclinics.com
604-789-2146

Investors:

Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley's franchise model; launch of new healthcare centers and the occurrence thereof; that the Company can bring healthcare to millions of Canadians; that new healthcare services can be added and that the Company will be positioned to be a market- leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that Kai Medical Laboratory will successfully win any US Government RFP; that the MedX Health pilot program will be successful; that Empower will place the MedX Health teledermatology product in health centers in North America; that the Company's products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company's business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; that the Company will be able to commence and/or complete build-outs and tenants improvements for Canadian clinics or Kai Medical Laboratory expansion inn 2Q 2021; that the sale of Sun Valley will close as anticipated; that general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.



View source version on accesswire.com:
https://www.accesswire.com/656437/Empower-Announces-Sale-of-Its-Cannabis-Related-Assets

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release

MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill

Fermi Announces New Agreements with Investment-Grade Hyperscaler and Third Quarter 2026 Financial Results12.11.2026 13:00:00 CET | Press release

DALLAS, TX / ACCESS Newswire / November 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced its third quarter 2026 financial results and multiple new agreements with an investment-grade hyperscaler to advance 600 megawatts ("MW") of power capacity at Project Matador. A conference call is scheduled for 9 a.m. Eastern Time / 2 p.m. British Time today, November 12, 2026. Accompanying slides and prepared remarks can be found at https://investor.fermiamerica.com. Participation details are included in this release. "Hyperscalers want sites that are ready with permitted power, and Fermi's Project Matador is one of few that can meet that demand today," said Lee McIntire, Fermi Chief Executive Officer. "Our headstart in speed to power is a key reason an investment-grade hyperscaler has signed up for 600 megawatts and committed more than $200 million up front to accelerate construction at Project Matador with an additional $90 mi

Nexteer Announces First Share Repurchase Programme of Up to US$60 Million12.11.2026 01:40:00 CET | Press release

HONG KONG, HK / ACCESS Newswire / November 11, 2026 / Nexteer Automotive today announced that its Board of Directors has approved, the Company's first share repurchase programme of up to US$60 million, equivalent to approximately HK$471 million. The programme reflects the Board's confidence in Nexteer's business and long-term prospects. The Group's strong liquidity position supports returning capital to shareholders while continuing to invest in the business and its future development. Disciplined Capital Allocation The programme complements Nexteer's dividend distributions and represents a further step in returning capital to shareholders. It follows the dividend paid out in July 2026 of approximately US$46 million, representing 45% of the Company's net income attributable to shareholders for the year ending December 31, 2025 -and the highest dividend payout ratio in the Company's history. Nexteer remains committed to disciplined capital allocation, balancing investment in the busines

GoodData.AI Launches the Agentic Serving Plane, a New Category of Enterprise Data Infrastructure for AI Agents10.11.2026 15:30:00 CET | Press release

SAN FRANCISCO, CA / ACCESS Newswire / November 10, 2026 / GoodData.AI, the open agentic analytics platform, today launched the Agentic Serving Plane, a governed execution layer designed for the high-concurrency, context-rich data workloads created by AI agents. The Agentic Serving Plane sits between enterprise data platforms and the applications, analytics experiences and agents that consume them. It provides workload serving, business semantics, contextual grounding, access control, and AI execution services through a common governed layer. The current enterprise data infrastructure was designed primarily for humans: occasional queries, predictable workloads, and access by known users. AI agents operate differently. A single business task can generate tens or hundreds of short-lived data operations as an agent investigates, reasons, and decides what to ask next. When many agents operate simultaneously, intermittent human querying becomes continuous, high-concurrency agentic demand. Ag

Envision Pharma Group appoints Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian10.11.2026 15:00:00 CET | Press release

FAIRFIELD, CT / ACCESS Newswire / November 10, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, has appointed Leigh Anne Siino as Senior Vice President of Commercial, Two Labs and Riparian. Siino will lead a team providing best-in-class launch and revenue management services to the biopharma community. Pharma and biotech companies across the industry seek suppliers who can support them from their earliest stages, often before they have built in-house commercial, market access, and revenue management capabilities. Two Labs provides commercialization services and consulting support as these companies prepare for and execute successful launches; Riparian offers consulting, managed services, and technology to manage and protect revenue as their therapies reach patients. Together, Envision's Two Labs and Riparian businesses offer a single, connected solution spanning launch and beyond. Under Siino's leadership, clients wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye